Category: 8-Slide Guide

The Digest’s 2024 Multi-Slide Guide to  Maximizing Bio-Renewable Energy from Wet Wastes

The Digest’s 2024 Multi-Slide Guide to Maximizing Bio-Renewable Energy from Wet Wastes

September 17, 2024 |

Most current wastewater plants recover <33% of incoming energy & have a negative energy balance. So, there’s an opportunity to increase net energy yield from municipal wastewater treatment. Yet, Anaerobic membrane bioreactors (AnMBRs) facilitate mainstream anaerobic digestion but previous AnMBRs suffer from high costs and energy inputs.  A research team proposed a project to resolve […]

Read More

The Digest’s 2024 Multi-Slide Guide to Maximizing Biogas Yield in small scale AD facilities

The Digest’s 2024 Multi-Slide Guide to Maximizing Biogas Yield in small scale AD facilities

September 16, 2024 |

Energy production from sewage sludge especially at small-scale using Anaerobic Digestion (AD) typically does not produce significant value with the current available AD technology due to low Carbon Conversion Efficiency (CCE) (generally less than 50%). A research team proposed a novel concept, which will overcome this problem and produce significant more energy in the form […]

Read More

The Digest’s 2024 Multi-Slide Guide to Origin Materials, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Origin Materials, the investment perspective

September 15, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Novonesis, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Novonesis, the investment perspective

September 12, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Yield10 Biosciences, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Yield10 Biosciences, the investment perspective

September 11, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Opal Fuels, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Opal Fuels, the investment perspective

September 10, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Ginkgo BioWorks, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Ginkgo BioWorks, the investment perspective

September 9, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Green Plains, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Green Plains, the investment perspective

September 6, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Aemetis, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Aemetis, the investment perspective

September 5, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More

The Digest’s 2024 Multi-Slide Guide to Neste, the investment perspective

The Digest’s 2024 Multi-Slide Guide to Neste, the investment perspective

September 4, 2024 |

A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]

Read More